Display options
Cite
Bedewy M, El-Maghraby S, Bedewy A. CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Res. 2013;48(2):121-7doi: 10.5045/br.2013.48.2.121.
Bedewy, M., El-Maghraby, S., & Bedewy, A. (2013). CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood research, 48(2), 121-7. https://doi.org/10.5045/br.2013.48.2.121
Bedewy, Magdy, et al. "CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma." Blood research vol. 48,2 (2013): 121-7. doi: https://doi.org/10.5045/br.2013.48.2.121
Bedewy M, El-Maghraby S, Bedewy A. CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Res. 2013 Jun;48(2):121-7. doi: 10.5045/br.2013.48.2.121. Epub 2013 Jun 25. PMID: 23826581; PMCID: PMC3698397.
Copy Download .nbib Format: NLM
Share it on

Blood Res. 2013 Jun;48(2):121-7. doi: 10.5045/br.2013.48.2.121. Epub 2013 Jun 25.

CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma.

Blood research

Magdy Bedewy, Shereen El-Maghraby, Ahmed Bedewy

Affiliations

  1. Military Medical Academy, Cairo, Egypt.

PMID: 23826581 PMCID: PMC3698397 DOI: 10.5045/br.2013.48.2.121

Abstract

BACKGROUND: Advances in the understanding of Hodgkin's lymphoma (HL) show various functions of infiltrating immune cells and cytokines in relation to clinical outcomes. The expression of CD163 and c-Met has been suggested to have a role in lymphoid malignancy. Thus, we evaluated the expressions of CD163, c-Met, and serum free light chain (sFLC) in relation to the clinicopathological features of patients with advanced classical HL (cHL).

METHODS: We assessed the expression of CD163 and c-Met in 34 patients with cHL through immunohistochemistry on the lymph node biopsy sections and the levels of pretreatment sFLC were estimated using ELISA.

RESULTS: High CD163 expression correlated with increased age, B symptoms, International Prognostic Score (IPS) ≥3, mixed cellularity subtype, and low response to treatment. Further, high c-Met expression correlated with increased age at diagnosis, leukocytosis, B symptoms, and lower chance to achieve complete remission. The sFLC levels correlated with increased age at diagnosis, lymphopenia, IPS ≥3, B symptoms, and lower complete remission rates.

CONCLUSION: In advanced cHL, increased expression of CD163 and c-Met showed a significant association with adverse prognostic parameters and poor response to treatment. Pretreatment high sFLC level also correlated with poor risk factors, suggesting its use as a candidate prognostic marker. A comprehensive approach for prognostic markers might represent a step towards developing a tailored therapeutic approach for HL.

Keywords: CD163; Free light chain; Hodgkin; c-Met

References

  1. Int J Cancer. 2005 Feb 10;113(4):678-82 - PubMed
  2. EMBO J. 1996 Nov 15;15(22):6205-12 - PubMed
  3. Am J Hematol. 2011 Dec;86(12):998-1000 - PubMed
  4. Blood. 2012 Oct 18;120(16):3280-7 - PubMed
  5. Int J Hematol. 2010 Dec;92(5):713-24 - PubMed
  6. J Clin Oncol. 2003 Sep 15;21(18):3431-9 - PubMed
  7. J Clin Oncol. 2013 Feb 20;31(6):692-700 - PubMed
  8. J Clin Oncol. 2007 Feb 10;25(5):579-86 - PubMed
  9. Haematologica. 2012 Apr;97(4):572-8 - PubMed
  10. N Engl J Med. 1998 Nov 19;339(21):1506-14 - PubMed
  11. Cancer Metastasis Rev. 2007 Dec;26(3-4):373-400 - PubMed
  12. Blood. 2012 Oct 25;120(17):3530-40 - PubMed
  13. N Engl J Med. 2010 Mar 11;362(10):875-85 - PubMed
  14. Clin J Am Soc Nephrol. 2008 Nov;3(6):1684-90 - PubMed
  15. Ann Oncol. 2007 Feb;18(2):376-80 - PubMed
  16. Eur J Pharmacol. 2006 Mar 8;533(1-3):319-26 - PubMed
  17. Immunogenetics. 2001 Mar;53(2):170-7 - PubMed
  18. Clin Chem. 2001 Apr;47(4):673-80 - PubMed
  19. J Clin Oncol. 2000 Feb;18(3):487-97 - PubMed
  20. Lab Invest. 2010 Sep;90(9):1346-56 - PubMed
  21. Histopathology. 2000 Apr;36(4):313-25 - PubMed
  22. Blood. 2001 Feb 15;97(4):1063-9 - PubMed
  23. Ann Oncol. 2012 Mar;23(3):736-742 - PubMed
  24. J Clin Oncol. 2009 Jul 10;27(20):3330-7 - PubMed
  25. Eur J Haematol. 2012 Apr;88(4):292-305 - PubMed
  26. Ann Rheum Dis. 2007 Jan;66(1):23-7 - PubMed
  27. Leuk Lymphoma. 2008 Sep;49(9):1668-80 - PubMed
  28. Br J Haematol. 2002 Oct;119(1):239-43 - PubMed
  29. Leukemia. 2009 Feb;23(2):215-24 - PubMed
  30. Clin Chem. 2002 Sep;48(9):1437-44 - PubMed
  31. Diagn Pathol. 2012 Jan 30;7:12 - PubMed
  32. Oncogene. 2000 Nov 20;19(49):5582-9 - PubMed
  33. Am J Clin Pathol. 2004 Nov;122(5):794-801 - PubMed
  34. Cancer Res. 1971 Nov;31(11):1860-1 - PubMed
  35. Leukemia. 2000 Feb;14(2):285-91 - PubMed
  36. Cytogenet Cell Genet. 1992;60(2):114-6 - PubMed
  37. Br J Haematol. 2004 Nov;127(3):305-7 - PubMed
  38. Blood. 2006 Jul 15;108(2):662-8 - PubMed

Publication Types